.RESEARCH STUDY FEATURE.06 August 2024.
A sizable randomized measured test along with cisgender women highlights the obstacles of fidelity to an everyday oral preexposure treatment regiment and also demonstrates that twice-yearly treatment of lenacapavir may sustain successful HIV deterrence amounts over 6 months.